Back to search
FDAFDA · Food and drugs·Recall number D-0609-2017

Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 900 mg/180 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017 Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-30).

Published March 29, 2017 · Recall initiated: March 7, 2017

Summary

FDA records drug Class III recall D-0609-2017, published March 29, 2017 and initiated March 7, 2017. Recalling firm: Pfizer Inc; Status: Terminated; Reported quantity: 9,666 units; Lot: Lot #: 03216025A, Exp.01/18. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pfizer Inc
Distributor
Nationwide within US
Lot
Lot #: 03216025A, Exp.01/18.
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 900 mg/180 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017 Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-30). recalled?

Yes. FDA published recall D-0609-2017 on March 29, 2017. Reported hazard: Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.

What should I do if I have this product?

Voluntary: Firm initiated · Letter